Pharmafile Logo

Kraeber (UK) Ltd

The family owned business, Kraeber & Co GmbH, is an independent, technology based enterprise which was founded on the 1st January 1980 in Hamburg. Hanseatic tradition together with courageous entrepreneurship characterize our company. We are committed to open and global competition which we stand up with our service capabilities. Our emphasis is the development, production, marketing and sales of active pharmaceutical ingredients (APIs) of the highest purity. Kraeber has evolved into a niche marketer and supplier. By continously innovating productions, we became the quality market leader in Europe and in other parts of the world for many of our products.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

No items found

Company Details

16 The Street, Saxon Street, Newmarket, Suffolk, CB8 9RU, United Kingdom
+44 (0)1638 731 297

 Latest Content from PMHub 

5 ways to engage HCPs in medical education

White Papers and Resources | February 16, 2024 | Wiley

How to bring credibility, trust and flexibility into your medical education programs

Navigating challenges of MedTech research with rare-disease patients

Authored by: Tom Donnelly, MedTech Director and Amanda Pirraglia, Associate Director. Published in Quirk's Magazine.

Did You Hear From Her? If Not Here’s What You Missed in Season 1 of the Award-Winning Season Podcast Series

What are some of the biggest gaps that women face in healthcare today?  “So many I could talk for hours!” said Shikha Jain, MD, FACP, President, CEO, Founder Women in Medicine....

Have you heard from her?

We’re referring to the renowned women leaders from across the healthcare landscape who were our guests on Season 1 of Medscape Education’s Hear From Her podcast series. The conversations touched...

Clinical trial considerations: Why diversity matters...

Diversity in clinical trials is crucial for understanding diseases and developing new treatments. Here's why diversity matters...

Rare disease market access – Launching orphan drugs in secondary markets: the Nordic and MENA regions

Join us live at 1.00pm (GMT)/2.00pm (CET)/8.00am (EST) on Thursday 29th February, to explore rare disease market access challenges and learn more about these high potential markets.

The pitfalls of cutting costs on systematic literature reviews: 11 common issues to avoid

Embarking on a systematic literature review is a critical step in evidence synthesis, providing a foundation for robust decision-making in the healthcare landscape. As with most things, there are ways...

Product launch: What market research when?

Get the insights you need, when you need them, for your product launch planning

Clinical trial considerations: Why digital matters...

Digital technology in healthcare is rapidly evolving. In this blog we delve into how digital solutions can help improve patient experience within clinical trials.